Supplemental B-Vitamins and Risk of Upper Gastrointestinal Cancers in the Women’s Health Initiative
Menée à l'aide de données d'une étude portant sur 159 401 femmes ménopausées dont 302 sont atteintes d'un cancer de l'estomac et 183 d'un cancer de l'oesophage (âge : 50-79 ans ; durée de suivi : 19 ans), cette étude analyse l'association entre une supplémentation en vitamines B et le risque de développer ces maladies
B-vitamins contribute to DNA synthesis, maintenance, and regulation. Few studies have examined associations of supplemental sources of B-vitamins with the incidence of upper gastrointestinal (GI) cancers [including gastric (GCA) and esophageal (ECA) cancers]; the only prior study to comprehensively examine such intakes reported potential elevated risks of ECA. We examined 159,401 postmenopausal women, ages 50?79?years at baseline, including 302 incident GCA and 183 incident ECA cases, over 19?years of follow-up within the Women?s Health Initiative observational study and clinic trials. Adjusted Cox regression models estimated hazard ratios (HR) and 95% confidence intervals (CI) for associations of supplemental B-vitamins [riboflavin (B2), pyridoxine (B6), folic acid (B9), or cobalamin (B12)] with GCA and ECA risk, respectively. Although HRs were generally below 1.0, we observed no statistically significant associations between supplemental intakes of any of the evaluated B-vitamins with the risk of GCA or ECA. As the first prospective study to comprehensively assess these associations, our findings do not corroborate prior research indicating potential harm from supplemental B-vitamin intake for upper GI cancer risk. This study adds evidence that supplemental intakes of B-vitamins may be used by postmenopausal women without regard to their relationship with upper GI cancer risk.